Novo Nordisk’s fast-acting mealtime insulin approved in the US

The US Food and Drug Agency (FDA) has given the go-ahead for marketing of a new fast-acting mealtime insulin from the Danish drug group Novo Nordisk.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Latest Top picks in English

Related articles